15 Current news of Sequenom
rss10-25-2011
Sequenom, Inc. announced the appointment of Suber Huang, M.D., to its ophthalmology clinical advisory board.Dr. Huang is President of the American Society of Retina Specialists and has served on the Steering Committee for the National Eye Health Education Program, an advisory board to the ...
08-16-2011
Sequenom, Inc. announced it has partnered with LifeCodexx AG for the commercialization of prenatal laboratory testing services in Europe. The companies have agreed to collaborate in the development and launch of a trisomy 21 laboratory developed test and other aneuploidies testing in Germany, ...
01-29-2009
Sequenom, Inc. announced that it has commenced an exchange offer to acquire all of the outstanding shares of common stock of EXACT Sciences Corporation in an all-stock exchange valued at approximately $41 million. Subject to the terms and conditions of the offer, each share of EXACT ...
01-28-2009
Sequenom, Inc. announced an agreement to acquire the complete AttoSense(TM) portfolio of tests along with certain other assets from privately held biotechnology company SensiGen LLC. SensiGen has been developing advanced gene-based molecular tests with diagnostic potential under a partnership ...
The Immune Tolerance Institute, Sequenom and the University of California, San Francisco to Develop Advanced Diagnostic Test for Severe Combined Immunodeficiency in Newborns
01-16-2009
The Immune Tolerance Institute, Inc. (ITI), and Sequenom, Inc. announced a collaboration to develop an advanced newborn screening test for severe combined immunodeficiency (SCID) based on the pioneering work of Jennifer Puck, MD, of the University of California, San Francisco (UCSF). A ...
Acquisition Would Enhance Sequenom's Position in Cancer Genomics and Noninvasive Cancer Diagnostics
01-13-2009
Sequenom, Inc. announced that it has submitted a proposal to the Board of Directors of EXACT Sciences Corporation to acquire all of the outstanding shares of common stock of EXACT Sciences in an all-stock transaction valued at approximately $41 million. Under the terms of the proposal, each ...
09-24-2008
Sequenom, Inc. announced that it has secured exclusive rights to fundamental patent rights for digital PCR technologies and methods through a licensing agreement with Genomic Nanosystems, LLC, a wholly owned subsidiary of the Cytonix Corporation. The exclusively licensed rights include United ...
01-25-2008
Sequenom, Inc. announced the approval of a protocol by the Institutional Review Board (IRB) at San Diego-based Sharp HealthCare, clearing the way to commence patient enrollment in a screening study to clinically assess the Company's noninvasive cell free fetal nucleic acid SEQureDx(TM) ...
01-03-2008
Sequenom, Inc. announced the New York State approval of the first noninvasive prenatal test based on Sequenom's SEQureDx(TM) Technology for Cell Free Fetal Nucleic Acid assessment. The Laboratory Developed Test (LDT) performed on a real-time PCR (RT-PCR) platform to detect Rhesus D (RhD) ...
01-31-2007
Sequenom, Inc. and Lenetix Medical Screening Laboratory, Inc., a provider of rapid genetic screening and diagnostic testing, announced that they have entered into a collaboration and license agreement to develop and commercialize a proprietary non-invasive prenatal Rhesus D (RhD) ...
